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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
temozolomide in combination with interferon alpha-2b a safe and effective treatment for
malignant melanoma.
Study Design: Review of three randomized controlled trials published in the United States and
Britain between 2003 and 2005.
Data Sources: Three non-blind randomized controlled trials were found via Cochrane library
and PubMed.
Outcomes Measured: Efficacy was measured by survival greater than or equal to 12 months,
with one (experimental) group receiving treatment with oral temozolomide (TMZ) and
subcutaneous interferon alpha-2b (IFN-∝2b) and the other (control) group receiving oral TMZ
alone. Safety was measured by rates of nausea with the same experimental and control groups.
Safety was also measured by adverse event rates, with one group receiving combination
treatment with IFN-∝2b in a body surface area-based (BSA) dose, and the other group receiving
combination treatment with IFN-∝2b in a fixed dose.
Results: Kaufman et al and Danson et al demonstrated increased survival at 12 months when
comparing treatment with TMZ + IFN-∝ to TMZ monotherapy (ABI 9.7% and 8%,
respectively). Danson et al also found increased rates of nausea with combination treatment
compared to TMZ alone (ARI 11%, NNH 10). Ritchtig et al showed a slightly increased rate of
adverse events with an increased dose of IFN-∝2b when combined with TMZ (ARI 1.1%, NNH
90). No statistical analyses were performed on the data.
Conclusions: Based on these results, it is inconclusive if TMZ + IFN-∝2b is a safe and effective
treatment for malignant melanoma. Although results on survival suggest a benefit to combination
treatment, statistical analysis is required. Results for safety demonstrated increased adverse event
and nausea rates both with the addition of IFN-∝2b and at increased doses of IFN-∝2b, however
small sample size and lack of statistical analysis make it difficult to assume the safety of
combination treatment.
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INTRODUCTION
Malignant melanoma is an aggressive cancer of melanocytes, the pigment-producing
cells of the skin.1 This paper evaluates three randomized, controlled trials (RCTs) comparing the
safety and efficacy of temozolomide (TMZ) in combination with interferon alpha-2b (IFN-∝2b)
in the treatment of malignant melanoma.
Melanoma is the leading cause of death due to skin disease, accounting for more than
8,000 deaths per year.2 The incidence of melanoma in the United States is increasing. The risk of
developing the disease for a Caucasian man born in 2010 is 1 in 39, and 1 in 58 for a Caucasian
woman.3 This is compared to a 1 in 500 chance for an individual born in 1935.3 In addition to the
lives lost to this aggressive skin disease, its toll can be measured in the financial burden it
carries. An individual who dies from melanoma loses an average of $413,000 in future earnings,
which translates to a total loss of $3.5 billion in earnings per year due to melanoma death.2
Additionally, an American loses 20.4 years of potential life due to a death from melanoma,
compared to an average of 16.6 years from other malignancies.2 This loss of potential life
highlights the great need to improve the treatment of this disease.
In 2012 there were an estimated 76,250 cases of melanoma, accounting for 4% of cancers
in men and 3% in women.4 Both the commonness and the lethality of the disease highlight the
importance to recognize and act upon its earliest signs. A pigmented lesion that is suspicious for
malignant melanoma often have one or more of the “ABCDE” characteristics, which include
asymmetry, irregular border, variegated color, diameter > 6 mm, and evolution. Identified risk
factors include freckles, fair complexion, red or blond hair, blue eyes, family history of
melanoma, the presence of multiple nevi, and those whose first sunburn occurred at an early
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age.4 The single most important prognostic factor for a melanoma is the depth of skin that it
penetrates. Ten year survival rate for a tumor that is < 1 mm thick is 95%, compared to 30% for
tumors that penetrate > 4 mm.4 Metastatic melanoma carries a 10% survival rate and has
historically been resistant to chemotherapy.4
Melanoma is usually treated by local excision, with the addition of sentinel lymph node
biopsy for tumors > 1 mm deep or with high risk histologic features.4 For regional recurrences in
extremities, isolated limb perfusion or melphalan and hyperthermia are used.3 Dacarbazine is
considered standard systemic chemotherapy and is associated with a 15% response rate.4,5 High
dose IFN-∝2b is also utilized but is associated with high toxicity.4
TMZ is an oral compound which shares an active breakdown product with dacarbazine.5
TMZ advantages over dacarbazine include better absorption when taken orally, and better
penetration in all tissues of the body since it does not require enzymatic activation in the liver.5
TMZ also has demonstrated better response in treating brain metastases due to its ability to
penetrate the blood-brain barrier.5 This is an important feature due to the propensity for
melanoma to metastasize to the brain. IFN-∝2b has been used in combination with dacarbazine
in the past and has shown improved tumor response rates but has not shown an increase in
survival.4
OBJECTIVE
The objective of this selective EBM review is to determine whether or not temozolomide
in combination with interferon alpha-2b is a safe and effective treatment for malignant
melanoma.
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METHODS
Adult men and women between the ages of 18 and 88 with malignant melanoma were
included in all three studies. Interventions studied were the use of TMZ in combination with
INF-∝2b. Comparisons were made between TMZ alone and TMZ in combination with IFN-∝2b
in a fixed (rather than BSA-based) dose. Outcomes measured were survival greater than or equal
to one year, rates of nausea, and adverse drug event rates. All three studies were randomized,
controlled trials.
All articles were published in peer-reviewed journals and were originally published in
English. Articles were researched via Cochrane library and PubMed using key words
“temozolomide interferon alpha melanoma”. Articles were selected based on relevance to my
clinical question and if they reported patient-oriented outcomes. Inclusion criteria were if studies
were randomized, controlled trials published between 1999 and the present. Exclusion criteria
were if patients were under 18 years of age. Statistics reported include RRI, ARI, NNH, RBI,
ABI, and NNT. Table 1 describes the demographics and characteristics of each study.

Vincento, Temozolomide, Interferon-∝2b and Melanoma

4

Table 1. Demographics & characteristics of included studies
Study

Type

# Pts

Age
(yrs)
1888

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Danson et
al5 (2003)

RCT

181

- Advanced metastatic
melanoma
- No previous chemotherapy
- Full recovery from
previous therapy
- Adequate bone marrow
reserve (neutrophils >
1,500/µL; platelets >
100,000 µ/L, Hgb > 10g/dL)
- Urea and creatinine < 1.5 x
the upper limits of
laboratory normal (ULN)
- Adequate hepatic function
(total bilirubin < 1.5 x ULN,
AST < 3 x ULN, alkaline
phosphatase < x ULN
- Adequate birth control
measures

- Pregnant or nursing
- Uncontrolled
vomiting that would
interfere with
administration of oral
medication
- biological therapy
within 4 weeks of
administration of
temozolomide
- If known HIV +
- Clinically
significant
comorbidity that
would interfere with
study evaluations

4

Experimental: oral
temozolomide 200
mg/m2 PO qd x 5d
with IFN-∝2b 5
mIU SQ every
MWF; Treatment
cycles repeated
every 28 days
VS Control:
temozolomide PO
200 mg/m2 at 8hour intervals for
a total of five
doses, repeated
every 28 days

Kaufman et
al6 (2005)

RCT

294

1875

- Melanoma stage IV with
no prior systemic therapy in
stage IV
- Karnofsky performance
status > 60%
- WBCs > 3,000/mm2,
platelets >100,000, serum
creatinine < 2x ULN,
bilirubin < 1.5 mg/dL
- Prior treatment (adjuvant,
stage III) had to be
completed at least 4 weeks
before study

- Evidence of CNS
metastases
- Major concomitant
illness of
cardiovascular,
respiratory, or renal
system
- Pregnant or nursing
- Primary ocular or
mucosal melanoma
- Nonmeasurable
disease

23

Experimental: oral
temozolomide 200
mg/m2/day, days
1-5 every 28 days,
in combination
with subcutaneous
IFN-∝2b 5
mU/m2; days 1, 3,
and 5 every week
VS Control:
Oral
temozolomide
(same dose) alone

Ritchtig et
al7 (2004)

RCT

47

3774

- Stage IV metastatic
melanoma that is surgically
incurable
- Eastern Cooperative
Oncology Group
performance status of 0-2
- Adequate organ function:
Hgb > 10g/dL, serum
creatinine < 1.5 x upper
limit of normal range
(ULN), leukocytes > 3,000
g/L, platelets > 100,000 g/L,
liver function < 3 x ULN,
alkaline phosphatase < 3 x
ULN, bilirubin < 2 x ULN
- Life expectancy > 12
weeks

Not indicated

0

Experimental:
temozolomide 150
mg/m2 days 1-5
PO every 28 days
with IFN-∝2b 10
MIU/m2 every
other day
VS
Control:
temozolomide 150
mg/m2 on days 15 every 28 days
with IFN-α2b in a
fixed dose of 10
mIU every other
day
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OUTCOMES MEASURED
All outcomes measured were patient-oriented evidence that matters (POEMs). Danson et
al and Kaufman et al measured survival greater than or equal to 12 months.5,6 The amount of
people in each group still living after 12 months were counted and reported as a percentage.
Adverse events were also studied. Ritchtig et al measured adverse drug events, including
neurological symptoms, drug-induced skin eruption, sepsis, and brain hemorrhage.7 Patients
reported any adverse events that they experienced during the course of treatment, and adverse
events were differentiated from common side effects such as nausea, vomiting, arthalgia,
myalgia, and headache. Danson et al measured the most common side effect of nausea.5 Patients
who reported nausea during the course of treatment were recorded and counted as a percentage
of the total population studied.
RESULTS
Three randomized controlled trials that reported dichotomous data were used in this
review. Two trials studied the combination of TMZ with IFN-∝2b compared to the use of TMZ
alone.5,6 One study analyzed the use of TMZ with IFN-∝2b in a BSA-based dose compared to
fixed dosing.7 Dosages of TMZ varied from 150 mg/m2 to 200 mg/m2, and it was given once
daily orally for five days once per 28-day cycle. TMZ dose frequency differed in the control
group of Danson et al in which it was given every 8 hours for a total of 5 doses for every 28-day
cycle.5 Dosages of IFN-∝2b ranged from 5 milliunits/m2 (mU/ m2) subcutaneously on days one,
three, and five to 10 million international units (mIU) subcutaneously on days one, three and
five. All three studies utilized 28-day treatment cycles.
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All studies required patients to have stage IV melanoma, however Kaufman et al
excluded patients who had metastases to the central nervous system.6 Both Kaufman et al and
Danson et al indicated that their patients must not have received previous chemotherapy for their
disease in Stage IV, however Ritchtig et al did not make this specification.5,6,7 The study by
Kaufman et al was performed in an outpatient setting, while Ritchtig et al and Danson et al did
not specify whether their studies were performed on an outpatient or inpatient basis.5,6,7 The
number of patients that withdrew from each study is indicated in Table 1.
In the study by Kaufman et al, the intent to treat population was made up of 280 patients,
139 in the TMZ arm, and 143 in the TMZ + IFN-∝2b arm.6 Of the intent to treat population, 35
patients in the TMZ + IFN-∝2b group demonstrated either complete or partial response,
compared to 18 patients in the TMZ group.6 Partial or complete response was defined as
remission or >50% decrease in disease bulk as measured by physical exam, CT, or MRI.6 These
measurements were performed before treatment and after every second cycle. Of these
individuals who demonstrated either partial or complete response, 17 of 35 patients in the TMZ +
IFN-∝2b group (48.6%) survived longer than 12 months, compared to TMZ alone where 7 of 18
patients (38.9%) survived longer than 12 months.6 This translated to a relative benefit increase
(RBI) of 24.9%, an absolute benefit increase of 9.7%, and a number needed to treat (NNT) of
11(Table 2). No statistical tests were performed on this data.
Danson et al measured one-year survival rates out of the total intent to treat population.5
Of those who received TMZ alone, 18% were alive at 12 months, compared to 26% of the group
who received TMZ + IFN-∝2b.5 This translated to a RBI of 44.4%, an ABI of 8%, and an NNT
of 13 (Table 2). No statistical tests were performed on this data.
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Table 2. Survival greater than or equal to 12 months
TMZ + IFNRelative
Study
TMZ alone
A2B
benefit
increase
(RBI)
Kaufman et
38.9%
48.6%
24.9%
al
Danson et al
18%
26%
44.4%

7

Absolute
benefit
increase
(ABI)
9.7%

Number
needed to treat
(NNT)

8%

13

11

Ritchtig et al noted the number of patients who experienced adverse drug events. For this
study it is important to differentiate adverse drug events, in which a patient is harmed by the
drug, from common side effects such as nausea, vomiting, arthralgia, and fatigue. Of the group
that received TMZ + IFN-∝2b in a BSA-based dose (control), 2 out of 20 experienced adverse
drug events, which included sepsis and brain hemorrhage.7 Of the group that received TMZ +
IFN-∝2b in a fixed dose (experimental), three out of 27 experienced adverse drug events, which
included two patients with neurological symptoms and one with a drug-induced skin eruption.7
Ritchtig et al does not indicate the severity nor the outcome of these events, nor does he perform
statistical tests to indicate if any significant difference was observed between the two groups.
These data translate to a relative risk increase (RRI) of 11.1% of a fixed versus weight-based
dose, an absolute risk increase (ARI) of 1.1%, and a number needed to harm (NNH) of 90 (Table
3). Referencing the dosages of each group from Table 1, it should be noted that the fixed dose of
IFN-∝2b for the experimental group of 10 mIU is far lower than the weight-based dose of the
control of 10 MIU/m2. Therefore the lower dosage of the control group is associated with fewer
adverse events.
The most common side effect reported in Danson et al was nausea.5 Nausea, in part,
represents the toxicity that the drug treatment regimen had on the patients, and is important to
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take note of because it influences the quality of life of these critical patients. In the group that
received TMZ alone, 39% experienced nausea, compared to 49% of those who received TMZ +
IFN-∝2b.5 This correlates with a RRI of 28.5%, ARI of 11%, and a NNH of 10 (Table 3).
Table 3. Adverse drug events and side effects
Control
Experimental Relative risk
Outcome
event rate
event rate
increase
(RRI)
Adverse
drug events
Nausea

0.10

0.111

11.1%

Absolute
risk
increase
(ARI)
1.1%

0.39

0.49

28.9%

11%

Number
needed to
harm (NNH)

10

90

DISCUSSION
Based on the results for survival at or greater than 12 months from Kaufman et al and
Danson et al (Table 2), one can see a modest increased benefit in the combination treatment of
TMZ and IFN-∝2b as opposed to using TMZ alone. Neither of the studies performed statistical
analyses on this particular data and therefore it is unknown if these findings are statistically
significant.
Analyzing the calculated NNT is perhaps the best way for both patients and academics
alike to appreciate the true benefit, or lack thereof, of the treatment of interest. The results from
Kaufman et al and Danson et al showed a NNT of 11 and 13, respectively, meaning that for
every 11-13 patients treated with the regimen of interest, one patient would benefit in the form of
surviving greater than or equal to 12 months. Although the NNT are relatively low, it is more
accurate to interpret the data in the context of the quality of the life that the addition of IFN-∝2b
is adding for these patients. The patients participating in these studies have stage IV melanoma,

Vincento, Temozolomide, Interferon-∝2b and Melanoma

9

which historically has been resistant to chemotherapy, and carries about a 10% survival rate.4
The poor survival rate highlights the importance of considering the adverse effects that these
drugs have in the interest of quality of life.
The rate of adverse events studied by Ritchtig et al resulted in a NNH of 90 (Table 3). A
high NNH translates to a low risk of harm, however, this number in this context is misleading for
two reasons. For one, the severity of the adverse events varies greatly. These events ranged from
sepsis and brain hemorrhage in the control group to neurological symptoms and drug-induced
skin eruption in the experimental group. The outcomes of these adverse events are not discussed.
Secondly, this measurement has a very small sample size of 47 patients total. The combination of
the wide range of adverse events and the small sample size makes it difficult to ascertain from
this data whether the addition of IFN-∝2b to TMZ is safe in the treatment of stage IV melanoma.
Danson et al observed an ARI in nausea of 11% with the addition of IFN-∝2b to TMZ
treatment. Statistical tests were not performed on the data, however with a NNH of 10 (Table 3),
one can ascertain that the combination treatment is associated with an increased risk of nausea.
This plays a role in the quality of life of the patients and should be taken into consideration when
choosing treatment options.
All of the studies included had limitations that should be discussed. For one, none of the
trials were blinded, which allows the potential for bias to be introduced into the study.
Additionally, Ritchtig et al had a relatively small sample size, with 20 patients in his control
group and 27 in the experimental.7 Kaufman et al excluded patients that had metastases to the
central nervous system,6 however one of the advantages of using TMZ over dacarbazine is that it
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is able to penetrate the blood-brain barrier,5 and therefore perhaps its full effects were not
observed.
TMZ is an oral drug that is nonenzymatically converted into its active form and is able to
penetrate the blood-brain barrier.5 It exerts its effects by DNA alkylation, which leads to breaks
in the DNA strands and apoptosis.8 It is widely used in the Unites States as an antineoplastic
agent for conditions such as glioblastoma multiforme, cutaneous T-cell lymphoma, melanoma,
Ewing sarcoma, and anaplastic astrocytoma.8 Warnings exist for its potential to cause
myelosuppression, nausea and emesis, hepatotoxicity, Pneumocystis jirovercii pneumonia, and
rarely, secondary malignancies.8
IFN-∝2b is commonly used as an antineoplastic agent, biological response modulator, or
immunomodulator for conditions such as hairy cell leukemia, lymphoma, melanoma, Kaposi
sarcoma, chronic hepatitis B and C, and condyloma acuminata.9 U.S. Boxed Warnings exist due
to its potential to cause or aggravate neuropsychiatric disorders, autoimmune disease, infectious
disorders, and ischemic disorders.9 The wide range of adverse effects that is associated with IFN∝2b may potentially limit its use.
CONCLUSION
It is difficult to definitively conclude whether the benefits of treatment with TMZ + IFN∝2b outweigh the risks. Although the combination treatment in both Kaufman et al and Danson
et al yielded improved survival, no statistical tests were performed on these results in order to
determine if there was a significant difference between groups.5,6 The studies also demonstrated
increased rates of adverse effects with combination treatment, but of unknown statistical
significance. Therefore further research should be aimed at determining the statistical
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significance of survival outcomes and rates of adverse effects in combination treatment of TMZ
and IFN-∝2b versus TMZ alone. Additionally, since a major advantage of TMZ over
dacarbazine, which is the current standard chemotherapy, is its ability to penetrate the bloodbrain barrier,5 further study should be aimed toward the effect of TMZ on patients with brain
metastases. This is particularly important due to the propensity of melanoma to metastasize to
the brain. The addition of more research, however, will not replace the importance of the
personal choice to undergo intensive treatment, but it will hopefully help guide families to make
the most educated decision possible.
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